DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.